HUADE VOICE | HUADE BIOTECH Partners with REKEYMED to Accelerate Functional Peptide Innovation Through AI

HUADE BIOTECH Partners with REKEYMED to Accelerate Functional Peptide Innovation Through AI

On July 8, 2026, Sichuan HUADE Bioengineering Co., Ltd. and RekeyMed officially signed a Strategic Cooperation Framework Agreement in Xiamen, China. The agreement was jointly signed by Professor Wenjin Yan, Chief Scientist of Active Peptides at REKEYMED, and Mr. Guoqiang Luo, General Manager of HUADE BIOTECH, marking the beginning of a long-term strategic partnership between the two companies.

This collaboration combines REKEYMED AI-powered peptide discovery platform with HUADE BIOTECH's industrialization and large-scale manufacturing capabilities. Together, the two companies will jointly advance the discovery of novel functional peptides for animal health, strain engineering, and commercial-scale biomanufacturing.

By integrating artificial intelligence into peptide research, the traditional discovery process is being fundamentally transformed. AI enables faster candidate screening, more accurate target prediction, and significantly higher discovery efficiency, accelerating the identification of functional peptide molecules with real-world value for the livestock industry. The partnership aims to deliver innovative, science-driven peptide solutions that address the evolving challenges of modern animal production.

Why This Partnership Matters: Transforming R&D for a Changing Livestock Industry

As the livestock industry faces increasing economic pressure, market expectations for feed additives are shifting toward scientifically validated efficacy and cost-effective solutions. Meeting these demands requires not only innovative products, but also a faster and more efficient R&D approach.

Leveraging years of expertise in biomaterials and bioactive peptide research, REKEYMED has developed an AI-driven discovery platform spanning polymeric biomaterials, bioactive materials, and functional peptides. Its strengths in molecular design, target prediction, and high-throughput peptide screening have already supported the successful commercialization of innovations in medical aesthetics, functional skincare, and biomedical materials. This collaboration marks a significant step in extending its AI peptide platform into the animal health sector.

 

Meanwhile, HUADE BIOTECH has built a fully integrated industrial platform covering gene design, strain engineering, recombinant expression, fermentation, and large-scale manufacturing. The company has successfully commercialized products including epidermal growth factor (EGF), trefoil factor 3 (TFF3), and antimicrobial peptides (defensins), while gaining deep insight into the cost structure, technical challenges, and practical needs of modern livestock production.

By combining REKEYMED AI-powered peptide discovery capabilities with HUADE BIOTECH's expertise in industrialization and commercial production, the two companies aim to establish a seamless innovation pipeline—from molecular discovery and product development to large-scale manufacturing and market application—bringing next-generation functional peptide solutions to the global animal health industry.

Partnership Focus: Advancing Functional Peptides Across Multiple Species and the Entire Value Chain

The partnership will focus on the development of next-generation functional peptide solutions for multiple livestock species, including poultry, swine, and aquaculture. By combining REKEYMED‘s  AI-powered peptide discovery platform with HUADE BIOTECH's expertise in strain engineering, recombinant expression, fermentation, and large-scale manufacturing, the two companies will jointly accelerate the discovery, development, and commercialization of targeted bioactive peptide products for animal health.

During the strategic meeting, both teams also discussed their long-term collaboration roadmap. Future efforts will focus on gaining a deeper understanding of the real-world needs of livestock producers, identifying species-specific health challenges across different production stages, and leveraging the existing peptide library to screen and prioritize candidate molecules with the greatest commercial and industrial potential.

Moving forward, the partnership will be supported through a dedicated joint venture platform and a long-term collaboration mechanism. The two companies will continue to work closely on joint R&D, strain development, process optimization, technology transfer, and commercial deployment, building an integrated innovation pipeline that bridges AI-driven peptide discovery with industrial-scale manufacturing for the global animal health industry.

About REKEYMED 

REKEYMED  is a biotechnology platform company dedicated to developing next-generation biomaterials through the integration of AI-driven molecular design, automated wet-lab experimentation, and high-throughput screening and validation. The company is committed to building a programmable, experimentally validated, transferable, and scalable biomaterials discovery platform that accelerates innovation from concept to commercialization.

Powered by its AI-native discovery engine and continuously expanding data infrastructure, REKEYMED is developing a versatile biomaterials platform spanning neural repair, tissue regeneration, metabolic regulation, skin rejuvenation, bioelectronics, cell and gene therapy (CGT) enablement, and biointerfaces. By transforming biomaterials research from an experience-driven to an AI-driven paradigm, the company is accelerating the translation of scientific discoveries into industrial applications.

In addition to its expertise in antimicrobial and antiviral peptides, RekeyMed has established strong capabilities in regenerative biomaterials. Its proprietary PLA/PCL nanocopolymer platform, which has completed regulatory filing in China, provides a compliant and scalable solution for regenerative biomaterials in topical skincare applications. More recently, REKEYMED entered into a strategic partnership with Jianyuan Pharmaceutical Technology Co., Ltd. to jointly develop next-generation regenerative biomaterials and peptide-based cosmetic ingredients.

About HUADE BIOTECH

Sichuan HUADE Bioengineering Co., Ltd. is an innovation-driven biotechnology company specializing in synthetic biology and the development of bioactive peptides and functional proteins. Over the years, the company has built proprietary technologies centered on its gene fusion expression platform, enabling the successful industrialization of products including epidermal growth factor (EGF), trefoil factor 3 (TFF3), and antimicrobial peptides (defensins). HUADE has also established an extensive repository of high-performance production strains, providing a strong technological foundation for continuous product innovation and large-scale manufacturing.

With years of experience serving the livestock industry, HUADE BIOTECH has developed a deep understanding of the sector's economic challenges and the practical needs of animal producers. Through its partnership with REKEYMED, the company aims to combine its expertise in industrialization and commercial-scale biomanufacturing with REKEYMED's advanced AI-driven molecular design capabilities, accelerating the development of innovative peptide solutions that deliver measurable value to modern animal health and nutrition.